Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market
December 13, 2019 14:07 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously...
CORRECTING and REPLACING – Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
December 12, 2019 09:54 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), please note that the pricing and...
Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
December 12, 2019 08:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN). (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced that it has entered into...
Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients
December 10, 2019 16:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care
November 19, 2019 16:05 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering
November 15, 2019 11:43 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company...
Diffusion Pharmaceuticals Announces $4.0 Million Public Offering
November 13, 2019 09:34 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new treatments...
Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
November 11, 2019 08:00 ET
|
Diffusion Pharmaceuticals Inc.
Commenced Patient Enrollment in Phase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke Reported Favorable Safety Data in Glioblastoma Multiforme Phase 3 Run-in Study CHARLOTTESVILLE,...
First Patient Enrolled in Diffusion Pharmaceuticals’ Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke
October 17, 2019 08:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 03, 2019 10:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...